Thio-4-PIOL

Thio-4-PIOL

File:Thio-4-PIOL.svg
Clinical data
Other names	5-(Piperidin-4-yl)isothiazol-3-ol
Drug class	GABAA receptor weak partial agonist or antagonist
ATC code	None
Identifiers
IUPAC name 5-piperidin-4-yl-1,2-thiazol-3-one
PubChem CID	10035301
ChemSpider	8210866
ChEMBL	ChEMBL109209
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H12N2OS
Molar mass	184.26 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CNCCC1C2=CC(=O)NS2
InChI InChI=1S/C8H12N2OS/c11-8-5-7(12-10-8)6-1-3-9-4-2-6/h5-6,9H,1-4H2,(H,10,11) Key:WUINUICOEAZPLK-UHFFFAOYSA-N

Thio-4-PIOL, also known as 5-(piperidin-4-yl)isothiazol-3-ol, is a GABA_A receptor weak partial agonist or antagonist related to 4-PIOL.

Pharmacology

The drug acts as a weak partial agonist or antagonist of the GABA_A receptor, with varying efficacy depending on the receptor complex's specific subunit composition. It shows E_maxTooltip maximal efficacy values of up to approximately 30% at α₅β₃γ_2S, α₄β₃δ, and α₆β₃δ GABA_A receptors, 4 to 12% at α₅β₂γ_2S, α₄β₂δ, and α₆β₂δ GABA_A receptors, and 0 to 4% at α₁β₃γ_2S, α₁β₂γ_2S, α₂β₂γ_2S, α₂β₃γ_2S, α₃β₂γ_2S, and α₃β₃γ_2S GABA_A receptors. Thio-4-PIOL shows greater efficacy at extrasynaptic GABA_A receptors than at synaptic receptors. It produces effects in animals including hypolocomotion and hyperlocomotion (dependent on dose), anxiogenic effects, pronociceptive effects, impaired spatial learning, and seizures.

Development

Thio-4-PIOL was first described in the scientific literature by 1997. The drug is unlikely to be a candidate for a therapeutic drug due to its undesirable effects, but may be useful in scientific research. It is one of the only GABA_A receptor agonists to have been comprehensively evaluated in terms of functional activities.

See also

• Thio-THIP
• Thiomuscimol
• Piperidine-4-sulphonic acid (P4S)